Houston-based Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM), a pharmaceutical company focusing on the treatment of specific types of cancer, is shaking up its C-suite following the resignation of its COO.
Annemarie Moseley plans step down as the company’s COO and executive vice president of clinical development, effective July 31. She will remain a consultant to Bellicum through January.
“I would like to thank Annemarie for her many contributions to the success of Bellicum, particularly in establishing…
Houston pharmaceutical company announces C-level changes syndicated post